PT  - JOURNAL ARTICLE
AU  - Anna Jones
AU  - Kay Rodgers
AU  - Debbie Jeffrey
AU  - Waqas I Ali
AU  - HJN Andreyev
TI  - Nivolumab-induced exocrine pancreatic insufficiency
AID  - 10.1136/flgastro-2021-102013
DP  - 2023 Mar 01
TA  - Frontline Gastroenterology
PG  - 167--170
VI  - 14
IP  - 2
4099  - http://fg.bmj.com/content/14/2/167.short
4100  - http://fg.bmj.com/content/14/2/167.full
SO  - Frontline Gastroenterol2023 Mar 01; 14
AB  - Immune checkpoint inhibition is the standard-of-care for many advanced cancers. Side effects of therapy may prevent optimal treatment of the cancer. Management of side effects is dominated by recommendations derived from oncological, not gastroenterological practice. We report a patient who developed pancreatic insufficiency during checkpoint inhibitor therapy with a programmed cell death receptor 1 inhibitor, nivolumab, which if not diagnosed would have prevented ongoing treatment. This is a problem which affects approximately 1 in 100 patients treated with this agent but is rarely recognised. Gastroenterologists need to be aware of the spectrum of gastrointestinal disorders which occur after immunotherapy to treat cancer.